TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

T. L. Lasho, A. Tefferi, J. D. Hood, S. Verstovsek, D. G. Gilliland, A. Pardanani

Research output: Contribution to journal › Article › peer-review

90 Scopus citations

Fingerprint

Dive into the research topics of 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients'. Together they form a unique fingerprint.